Taken together, our findings suggest that IL-6 and RBP4 may function as biomarkers of poor prognosis and may represent potential therapeutic targets, particularly in CRC cases linked to inflammation and obesity. The gene discussed is RBP4; the disease is colorectal carcinoma.